Trial | NCT01137084  Report issue

Title

Liver Transplantation Results in Hepatocellular Carcinoma Patients With Immunosuppression Without Steroids

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    300
The purpose of this study was to evaluate the safety and efficacy of a steroid-free immunosuppression protocol in Hepatocellular Carcinoma (HCC) patients.
Study Started
Jan 31
2005
Primary Completion
Jan 31
2008
Study Completion
Dec 31
2009
Last Update
Jun 04
2010
Estimate

Drug solu medrol

total dose 20mg/kg, including first dose 10mg/kg, rest of drug given within one weeks after liver transplantation

Drug a steroid-free immunosuppression protocol

receive immunosuppression with Basiliximab(20mg/day,twice following transplantation) and tacrolimus(0.06/kg/d,twice a day) without steroids.

a steroid immunosuppression protocol Active Comparator

a steroid-free immunosuppression protocol Active Comparator

without steroid

Criteria 

Inclusion Criteria:

All liver transplantation patients with hepatocellular carcinoma in our center between Jan 2005 and Dec 2009 were potentially eligible for enrollment

Exclusion Criteria:

the recipient pass away within 3 month following up liver transplantation
Inability to provide written informed consent prior to study entry
acute rejection are treated only with steroids
No Results Posted